1. ALLA AKTIER
  2. NYHETER
  3. ALZINOVA

Alzinova

Nyheter Alzinova Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Alzinova presents at Erik Penser Bank's Investor Day on November 23rd

Alzinova AB (publ) (FN STO: ALZ) ("Alzinova" or the "Company"), today announces that Alzinova's CEO, Kristina Torfgård, will present the Company at Erik Penser Bank's Investor Day on November 23 in Stockholm. The presentation, which will be broadcast live, will be held at 15.45-16.10 in room 2.

On November 23, Erik Penser Bank arranges the fourth Investor day of the year. Alzinova's CEO Kristina Torfgård will present Alzinova and talk about the company's preparations for the upcoming phase 2 study with the vaccine candidate ALZ-101. The presentation, which will be held at 15.45-16.10 in room 2, will be broadcast live on Erik Penser Bank's YouTube channel Penser Play. For more information about the event visit: https://www.linkedin.com/events/bolagsdag23-117123625170153447424/about/

For more information, please contact:
Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail:  kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Attachments
Alzinova presents at Erik Penser Bank's Investor Day on November 23rd

Datum 2023-11-20, kl 15:00
Källa MFN
Bifogade filer
Alzinova presents at Erik Penser Bank's Investor Day on November 23rd